Leveraging world-leading expertise from the fields of immunology, beta cell biology, materials science and immuno-oncology to transform the treatment of Type 1 Diabetes, EMC2 Bio is developing an antibody-nanoparticle conjugate (ANC) designed to target genetic cargo specifically to pancreatic β cells. The cargo will target gene networks that modulate the interactive crosstalk between the β cell and the immune system in ways that protect the β cell from immune detection and destruction, by engaging the same mechanisms employed by cancer cells to escape immune surveillance. EMC2 Bio is initiating a seed financing to accelerate the completion of key IND-supporting preclinical experiments and activities.